Mice expressing constitutively active FGFR4 developed cardiac remodeling despite normal serum phosphate levels, whereas global and cardiac-specific FGFR4 knockout mice were protected from cardiac remodeling despite CKD-associated hyperphosphatemia. This evidence concerns the gene FGFR4 and chronic kidney disease.